This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Mark Your Calendar for Next Year's Event!
May 9-12, 2022Hynes Convention Center, Boston

Arthur Levin, PhD
Chief Scientific Officer at Avidity Biosciences, Inc.

Profile

Arthur Levin is a key opinion leader in the RNA therapeutics field. He serves as the CSO at Avidity Biosciences Inc. Previously, he held Senior levels positions at mRiragen, Santaris Pharma, and Ionis Pharmaceuticals. He played key roles in developing numerous oligonucleotides, including the first approved antisense drugs and the first microRNA-targeted therapeutic in clinical trials. He has three decades of experience in drug development from discovery through drug registration. Dr. Levin has published over 60 scientific articles and several of the most cited reviews in the field. He is on the scientific advisory boards of multiple institutions. Dr. Levin received a doctorate in toxicology from the University of Rochester.

Agenda Sessions

  • ROOM 204AB: Engineering Antibody Oligonucleotide Conjugates (AOCs): Taking Receptor-Mediated Uptake One Step Further

    11:15am
  • FEATURED MINI-SYMPOSIUM AND LIVE PANEL DISCUSSION WITH LIVE Q&A: Targeted Delivery of Oligonucleotides: Tissue-Specific Challenges and Novel Conjugation Strategies

    11:30am